Ertugliflozin

Drug Profile

Ertugliflozin

Alternative Names: MK-8835; PF-04971729; PF-4971729

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 01 Nov 2016 Merck and Pfizer announce intention to submit regulatory applications outside USA by 2017
  • 15 Sep 2016 Efficacy and adverse events data from a phase III trial in Type-2 diabetes mellitus released by Merck Sharp & Dohme
  • 01 Sep 2016 Merck and Pfizer completes a phase III trial in Type-2 diabetes mellitus (Adjunctive therapy) in USA, United Kingdom, Hungary, Bulgaria and Romania (NCT01986855, EudraCT2013-003587-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top